Immunomic Therapeutics launches The Cancer Discovery Incubator Award.
The award will enable and accelerate beginning ventures with the capacity for measurable change in oncology health. The goal is to empower the beneficiary to conduct proof-of-concept experiments and ultimately, attract funding, partnerships, and fuel growth.
ITI wins "Life Science Company of the Year"
Immunomic Therapeutics, Inc. is the proud recipient of Tech Council of MD's "Life Science Company of the Year". Celebrated at the Industry Awards, it is the only awards ceremony that honors the best in Maryland’s life science and technology community. This celebration is one of Maryland’s largest and most prestigious award ceremonies and recognizes executives, businesses, and innovative technology developed in Maryland and the surrounding regions.
Dr. Duane Mitchell, currently leading research studies at the University of Florida with his mRNA transfected DC vaccine
that codes for pp65 and LAMP for people that suffer from Glioblastoma, received Top 10 Clinical Research Achievement Awards recognition for their ATTAC clinical trial.
ITI is looking forward to the ATTAC II trial results, which include testing full-length LAMP!
Dec 7-9, 2016 | Boston, MAImmunization and Vaccine Summit
January 11-15, 2017 | San Francisco, CAJP Morgan Healthcare Conference
February 23-25, 2017 | Orlando, FLASCO SITC
April 10-12, 2017 | Washington, DCWorld Vaccine Congress
April 27-28, 2017 | Bethesda, MDBioTech17
We Work For Health
"We Work for Health" partnering with ITI
We Work For Health is a grassroots initiative that shows how biopharmaceutical research and medical innovation work together to create a strong, vibrant economy and a healthier America. We unite biopharmaceutical companies with business and community partners to raise awareness about the vital role we all play in delivering life-saving and life-enhancing advancements in medicine, while educating elected leaders on the impact that public policies have on our ability to continue to innovate.